Skip to main content
IMMUPHARMA PLC logo

IMMUPHARMA PLC — Investor Relations & Filings

Ticker · IMM ISIN · GB0033711010 LEI · 213800VZKGHXC7VUS895 IL Professional, scientific and technical activities
Open in API
Filings indexed 443 across all filing types
Latest filing 2020-09-29 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL IMM

About IMMUPHARMA PLC

https://www.immupharma.co.uk/

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company's primary focus is on creating novel treatments for serious medical conditions with significant unmet needs. Its core activities involve advancing a pipeline of drug candidates through research and various stages of clinical development, leveraging its expertise in peptide technology.

Recent filings

Filing Released Lang Actions
Share Subscription into Incanthera plc
Share Issue/Capital Change Classification · 1% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' header and the concluding boilerplate text referencing RNS, the London Stock Exchange, and the Financial Conduct Authority (FCA). The content details a specific corporate action: ImmuPharma PLC subscribing for shares in another company (Incanthera plc), which constitutes a material event announcement. Since this is a general regulatory announcement that doesn't fit the specific categories like Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or Capital Change (SHA), the most appropriate classification is the general regulatory filing category, RNS.
2020-09-29 English
Share Subscription into Incanthera plc
Capital/Financing Update Classification · 1% confidence The document announces that ImmuPharma PLC has executed a subscription agreement to purchase shares in another company, Incanthera plc, following its IPO. This action involves the acquisition of a significant equity stake (15.35%) in another entity. This falls under corporate financing activities, specifically an investment/subscription for shares, which aligns best with the 'Capital/Financing Update' category. It is not a standard regulatory report (10-K, IR, ER) nor a management change or dividend notice. It is a specific transaction related to capital structure/investment.
2020-09-29 English
Repayment of Convertible Security
Capital/Financing Update Classification · 1% confidence The document begins with 'RNS Number' and is dated '22 September 2020'. It discusses a specific corporate action: the 'Repayment of Convertible Security' involving Lind Global Macro Fund and L1 Capital. The text concludes with standard boilerplate language referencing 'RNS, the news service of the London Stock Exchange' and compliance with EU regulations. This structure is characteristic of a general regulatory news service announcement, which fits the definition of a Regulatory Filing (RNS) as a miscellaneous announcement that doesn't fit the more specific categories like ER, CAP, or DIV. Given the short length (4424 chars) and the nature of the announcement (a specific corporate event update), RNS is the most appropriate classification.
2020-09-22 English
Repayment of Convertible Security
Capital/Financing Update Classification · 1% confidence The document announces a specific corporate action: the 'Repayment of Convertible Security' involving Lind Global Macro Fund, LP and L1 Capital Global Master Opportunities Fund. This action directly relates to the company's financing structure and debt/security obligations. This fits best under the 'Capital/Financing Update' category, which covers fundraising, financing activities, or capital structure changes. It is not an earnings release, a major regulatory filing like a 10-K, or a general regulatory announcement (RNS), as it concerns a specific financial transaction.
2020-09-22 English
Update on submission to the FDA for a Special Protocol Assessment (SPA) for the forthcoming international Phase III trial of Lupuzor™ in Lupus Patients
Legal Proceedings Report Classification · 1% confidence The document is a short announcement dated September 11, 2020, providing an update on the status of a Special Protocol Assessment (SPA) submission to the FDA regarding the Phase III trial for Lupuzor™. It references a previous announcement and states that the company will update the market when a response is received. Given its brevity (3596 characters) and its function as an update on regulatory/clinical progress rather than a full financial report (like 10-K or IR) or a formal regulatory filing itself, it fits best as a general Regulatory Filing or an announcement related to ongoing operations. Since it is an update on a specific regulatory/clinical process, and not a standard earnings release (ER) or a formal report publication announcement (RPA) about a major document release, the most appropriate general category for miscellaneous corporate updates that don't fit elsewhere is RNS (Regulatory Filings). It is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP).
2020-09-11 English
Update on submission to the FDA
Legal Proceedings Report Classification · 1% confidence The document starts with 'RNS Number' and contains standard regulatory boilerplate language from the London Stock Exchange's news service ('This information is provided by RNS, the news service of the London Stock Exchange.'). The content is a brief update regarding a submission to the FDA concerning a Phase III trial for a drug (Lupuzor™). This is a time-sensitive, non-periodic corporate announcement that does not fit the definitions for 10-K, ER, IR, or DIV. Since it is a general regulatory announcement distributed via RNS and is not a specific filing type like DIRS, MANG, or CAP, the most appropriate classification is the general regulatory filing category.
2020-09-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.